Argentina’s latest cannabis law established new regulations for its cannabis industry framework.
Argentina, which legalized medical cannabis and hemp in 2022, created the Regulatory Agency for the Hemp and Medicinal Cannabis Industry (ARICCAME) in January of this year to promote and administer the country’s cannabis industry, and on August 4th the agency released a decree outlining several new regulations that will be enacted (1,2).
“The publication of this decree marks the dawn of a new age in Latin America when it comes to industrial hemp and cannabis,” said Lorenzo da Silva, President of the Latin American Industrial Hemp Association (LAIHA) (1). “Argentina, due to its geographical positioning and land availability, long history in agriculture and a commodity-centered economy, is the most suitable country in all of Latin America to develop a sturdy and sustainable hemp industry.”
The decree itself echoed the promotion of the various advantageous positions of Argentina to produce cannabis and hemp (1). The government has stated that it aims to use cannabis production to improve regional economies, enhance its exports, and improve product development and research (1).
As newly mandated, the tetrahydrocannabinol (THC) limit for hemp is set at 1% (1). Cannabidiol (CBD) products remain legal only as imports for patients (1). Cannabis will be permitted for medical purposes, veterinary use, nutritional and cosmetic uses, plus research (3).
The ARRICAME is intended to unify the administrative process of the industry and will oversee consumer safety, promote scientific research, and work with institutions of higher learning and state agencies (1). A new 20-person advisory board for the ARRICAME must include representatives from various relevant organizations and half of the members must be either women or transgender (1).
"There is no possibility of industry development without a federal perspective of support for regional economies with added value,” explained Gabriel Giménez, a board member of ARICCAME (2). “We have the opportunity to create quality employment, impact on the domestic market, and, above all, decent wages. That is already a concrete possibility. We have the responsibility to bring industrial hemp to small and medium-sized producers."
References
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.